AKBA vs BIIB · rev $102.7M vs P/E 21, rev $9.89B
Akebia Ther (AKBA) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Latest reported AKBA revenue for 2026-06-30 was $102.7M. Net income was -$18.0M. Revenue was up 91.8% from 2026-03-31 to 2026-06-30. AKBA currently screens at market cap $260.1M.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
AKBA currently screens at market cap $260.1M. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the AKBA and BIIB stock pages for the full models.
Not investment advice.